Compare EYPT & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EYPT | MMI |
|---|---|---|
| Founded | 1987 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2005 | 2013 |
| Metric | EYPT | MMI |
|---|---|---|
| Price | $13.97 | $31.74 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | ★ $31.80 | $28.00 |
| AVG Volume (30 Days) | ★ 1.4M | 183.6K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.78% |
| EPS Growth | N/A | ★ 84.38 |
| EPS | N/A | ★ N/A |
| Revenue | $7,539,000.00 | ★ $719,700,000.00 |
| Revenue This Year | N/A | $14.04 |
| Revenue Next Year | $3,115.57 | $11.35 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.41 | $24.43 |
| 52 Week High | $19.11 | $33.62 |
| Indicator | EYPT | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 65.99 |
| Support Level | $12.01 | $27.47 |
| Resistance Level | $14.52 | N/A |
| Average True Range (ATR) | 1.05 | 0.84 |
| MACD | 0.08 | 0.19 |
| Stochastic Oscillator | 51.38 | 92.63 |
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.